1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

BioNotebook: One deal ends for Vanda, Novartis; five new agreements begin

 
• By Mandy Jackson

Vanda, Novartis settle Fanapt dispute; Genentech, Phylogica partner on antibiotics; Janssen licenses Sevion antibody platform; Pfizer accesses Philogen antibodies; Tiziana licenses Novimmune asset; and EpiVax applies Novozymes technology.

Vanda, Novartis settle Fanapt dispute; Genentech, Phylogica partner on antibiotics; Janssen licenses Sevion antibody platform; Pfizer accesses Philogen antibodies; Tiziana licenses Novimmune asset; and EpiVax applies Novozymes technology.

Vanda, Novartis end arbitration proceedings over Fanapt

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

More from Therapy Areas